125 related articles for article (PubMed ID: 30414194)
1. The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitis.
Lee K; Pouldar D; Shiu J; Elsensohn A; de Feraudy S
J Cutan Pathol; 2019 Feb; 46(2):165-167. PubMed ID: 30414194
[No Abstract] [Full Text] [Related]
2. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
[TBL] [Abstract][Full Text] [Related]
3. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
[TBL] [Abstract][Full Text] [Related]
4. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
Henning A; Agnese D; Chung CG
J Cutan Pathol; 2021 Nov; 48(11):1423-1426. PubMed ID: 34189749
[TBL] [Abstract][Full Text] [Related]
5. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
[TBL] [Abstract][Full Text] [Related]
6. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
7. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
MacArthur TA; Fahy AS; Jakub JW
Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
[TBL] [Abstract][Full Text] [Related]
8. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
[No Abstract] [Full Text] [Related]
9. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
[TBL] [Abstract][Full Text] [Related]
10. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
[TBL] [Abstract][Full Text] [Related]
11. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
[No Abstract] [Full Text] [Related]
12. Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy.
Casale F; Tchanque-Fossuo C; Stepenaskie S; Durkin J
Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499413
[TBL] [Abstract][Full Text] [Related]
13. Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
Hsu AC; Kokot NC; Eisenberg BL; Thomas JS
Oral Oncol; 2020 Dec; 111():104899. PubMed ID: 32665184
[TBL] [Abstract][Full Text] [Related]
14. Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma.
Cilento MA; Klein O; Egan E; Roberts-Thomson R
Australas J Dermatol; 2022 Aug; 63(3):e222-e225. PubMed ID: 35666757
[TBL] [Abstract][Full Text] [Related]
15. Rash after a single injection of T-VEC.
Wagenknecht D; Kohlmann J; Rütten A; Ziemer M
J Dtsch Dermatol Ges; 2019 Jun; 17(6):649-651. PubMed ID: 30920764
[No Abstract] [Full Text] [Related]
16. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
17. Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy.
Danesh M; Faulkner-Jones B; Desai A; Kim CC
JAMA Dermatol; 2019 Apr; 155(4):496-497. PubMed ID: 30758504
[No Abstract] [Full Text] [Related]
18. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.
Soliman H; Hogue D; Han H; Mooney B; Costa R; Lee MC; Niell B; Williams A; Chau A; Falcon S; Khakpour N; Weinfurtner RJ; Hoover S; Kiluk J; Rosa M; Khong H; Czerniecki B
Clin Cancer Res; 2021 Feb; 27(4):1012-1018. PubMed ID: 33219014
[TBL] [Abstract][Full Text] [Related]
19. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
[TBL] [Abstract][Full Text] [Related]
20. Talimogene Laherparepvec Use in Kidney Transplant Recipient.
Gupta M; Brennan DC; Alhamad T
Transplantation; 2020 Apr; 104(4):e109-e110. PubMed ID: 31815902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
